Mirum Pharmaceuticals Authorized Livmarli Tablet for Alagille Syndrome
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy MIRM?
Mirum Pharmaceuticals announced that Health Canada has authorized the tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille syndrome. Livmarli had previously been authorized in Canada as an oral solution for patients aged 12 months or older. The new tablet formulation offers an additional dosing option for patients weighing 22 kg or more who can swallow tablets. "LIVMARLI's tablet formulation provides an important new option for patients with ALGS," said Jamie Twiselton, general manager, Mirum Pharmaceuticals Canada. "With a liquid formulation for younger patients and a convenient one tablet per dose option available for older patients, LIVMARLI now provides greater dosing flexibility, supporting continuity of care as patients with ALGS age."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIRM
Wall Street analysts forecast MIRM stock price to fall
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 102.830
Low
81.00
Averages
102.33
High
140.00
Current: 102.830
Low
81.00
Averages
102.33
High
140.00
About MIRM
Mirum Pharmaceuticals, Inc. is a rare disease company with a global footprint of approved products and a pipeline of investigational medicines. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mirum Pharmaceuticals Grants Stock Awards to New Employees
- Stock Option Grants: On February 10, 2026, Mirum Pharmaceuticals granted 163,040 non-qualified stock options to 37 new employees at an exercise price of $100.91 per share, aimed at attracting and retaining key talent to enhance the company's competitive edge in the rare disease sector.
- Restricted Stock Units: The company also awarded 219,090 restricted stock units (RSUs) that will vest over three years, ensuring long-term commitment from new hires, which is crucial for maintaining stable human resources for future product development and market promotion.
- Performance Stock Units: Additionally, 48,880 performance stock units (PSUs) were granted, with vesting conditions tied to net product sales levels in 2027 and 2028, reflecting the company's performance-driven incentive mechanism aimed at boosting sales performance and driving growth.
- Strategic Development Plan: This stock award program complies with Nasdaq listing rules, demonstrating Mirum's commitment to attracting high-quality talent, with the goal of driving ongoing strategic investments in the development and market expansion of rare disease medications.
See More
Mirum Pharmaceuticals Grants Stock Awards to New Employees
- Stock Option Grants: On February 10, 2026, Mirum Pharmaceuticals granted 163,040 non-qualified stock options to 37 new employees at an exercise price of $100.91 per share, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the rare disease sector.
- Restricted Stock Units: Additionally, 219,090 restricted stock units (RSUs) were awarded, which will vest over three years, ensuring stability among new employees during their tenure and thereby improving team cohesion and execution capabilities.
- Performance Stock Units: Mirum also granted 48,880 performance stock units (PSUs) with vesting contingent on achieving net product sales targets in 2027 and 2028, reflecting the company's focus on performance-driven incentives to motivate employees towards sales goals.
- Compliance with Inducement Plan: All awards comply with Nasdaq Listing Rule 5635(c)(4), ensuring that the company attracts talent while adhering to regulatory standards, which enhances investor confidence and improves corporate governance.
See More
Warning Signs for Overbought Healthcare Stocks
- Overbought Signals: As of February 2, 2026, three stocks in the healthcare sector are showing overbought signals with RSI values exceeding 70, indicating potential short-term pullback risks that investors should be cautious about.
- Brookdale Senior Living: This company's stock is in an overbought state with an RSI of 80.4, reflecting strong price momentum but also suggesting possible price adjustment risks, prompting investors to monitor market developments closely.
- Amicus Therapeutics Acquisition: Amicus Therapeutics announced its acquisition by BioMarin, with its stock price surging approximately 139% over the past six months to $14.29, while its RSI of 80.4 indicates strong market interest but also warns of potential corrections.
- Mirum Pharmaceuticals Performance: Mirum Pharmaceuticals is also in an overbought condition, and investors should pay attention to its RSI and market performance to assess future investment risks and opportunities.
See More
Mirum Pharmaceuticals Shows Significant Growth in 2025 Performance
- Significant Revenue Growth: Mirum Pharmaceuticals generated $372.4 million in revenue for the nine months ending September 30, 2025, reflecting a 56.8% year-over-year increase, indicating strong market performance despite ongoing unprofitability, laying a foundation for future profitability.
- Quarterly Profit Milestone: In Q3 2025, Mirum reported a rare net profit of $2.9 million, a significant turnaround from a net loss of $14.2 million in the same quarter last year, marking a crucial step toward achieving consistent profitability and potentially attracting more investor interest.
- Future Sales Expectations: The company anticipates net product sales of $520 million for the full 2025 fiscal year, representing at least a 54.4% increase compared to 2024, with projections for 2026 sales reaching between $630 million and $650 million, showcasing robust market demand and growth potential.
- Acquisition Impact: Mirum's recent acquisition of Bluejay Therapeutics for $620 million, while likely to negatively affect short-term profitability due to acquisition costs, is expected to enhance revenue and earnings in the long run by expanding its product lineup and strengthening market competitiveness.
See More
Mirum Pharmaceuticals Reports Third Quarter Profit Amid Slowing Growth
- Third Quarter Profit: Mirum Pharmaceuticals reported a net profit of $2.9 million in Q3 2025, a significant improvement from a net loss of $14.2 million in the same quarter last year, indicating notable progress towards profitability despite remaining unprofitable overall.
- Strong Revenue Growth: For the nine months ending September 30, 2025, Mirum generated $372.4 million in revenue, a 56.8% year-over-year increase, with expectations of $520 million in net product sales for the full fiscal year 2025, reflecting robust market demand.
- Acquisition Impact: The recent acquisition of Bluejay Therapeutics for $620 million may negatively affect short-term profitability due to acquisition costs, but it is expected to enhance revenue and earnings potential in the long run by expanding the product lineup.
- Cautious Future Outlook: While Mirum anticipates net sales of $630 million to $650 million in 2026, representing a 23.1% growth rate, the slowing sales growth raises concerns about the timeline for achieving consistent profitability, necessitating careful risk assessment by investors.
See More
Mirum Pharmaceuticals' Stock Doubles, Poised for Further Gains in 2026
- Positive Cash Flow: Mirum Pharmaceuticals achieved positive cash flow from operations in 2025, marking a significant milestone for a small biotech firm, which is expected to enhance investor confidence and drive stock price appreciation.
- FDA Drug Approvals: In 2025, Mirum received FDA approvals for Ctexli and Livmarli, targeting rare bile acid synthesis disorders and cholestatic pruritus, respectively, which are anticipated to significantly boost revenue and expand market share.
- Acquisition of Bluejay Therapeutics: On January 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding the promising therapy brelovitug for chronic hepatitis delta virus to its pipeline, potentially providing strong momentum for future revenue growth.
- Clinical Trial Catalysts: Mirum is set to announce results from the Phase 2B trial of volixibat in Q2 2026, and if approved, it could fill a treatment gap for primary sclerosing cholangitis in the U.S., further propelling the company's stock price upward.
See More
Mirum Pharmaceuticals Grants Stock Awards to New Employees
- Stock Option Grants: On February 10, 2026, Mirum Pharmaceuticals granted 163,040 non-qualified stock options to 37 new employees at an exercise price of $100.91 per share, aimed at attracting and retaining key talent to enhance the company's competitive edge in the rare disease sector.
- Restricted Stock Units: The company also awarded 219,090 restricted stock units (RSUs) that will vest over three years, ensuring long-term commitment from new hires, which is crucial for maintaining stable human resources for future product development and market promotion.
- Performance Stock Units: Additionally, 48,880 performance stock units (PSUs) were granted, with vesting conditions tied to net product sales levels in 2027 and 2028, reflecting the company's performance-driven incentive mechanism aimed at boosting sales performance and driving growth.
- Strategic Development Plan: This stock award program complies with Nasdaq listing rules, demonstrating Mirum's commitment to attracting high-quality talent, with the goal of driving ongoing strategic investments in the development and market expansion of rare disease medications.
See More
Mirum Pharmaceuticals Grants Stock Awards to New Employees
- Stock Option Grants: On February 10, 2026, Mirum Pharmaceuticals granted 163,040 non-qualified stock options to 37 new employees at an exercise price of $100.91 per share, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the rare disease sector.
- Restricted Stock Units: Additionally, 219,090 restricted stock units (RSUs) were awarded, which will vest over three years, ensuring stability among new employees during their tenure and thereby improving team cohesion and execution capabilities.
- Performance Stock Units: Mirum also granted 48,880 performance stock units (PSUs) with vesting contingent on achieving net product sales targets in 2027 and 2028, reflecting the company's focus on performance-driven incentives to motivate employees towards sales goals.
- Compliance with Inducement Plan: All awards comply with Nasdaq Listing Rule 5635(c)(4), ensuring that the company attracts talent while adhering to regulatory standards, which enhances investor confidence and improves corporate governance.
See More
Warning Signs for Overbought Healthcare Stocks
- Overbought Signals: As of February 2, 2026, three stocks in the healthcare sector are showing overbought signals with RSI values exceeding 70, indicating potential short-term pullback risks that investors should be cautious about.
- Brookdale Senior Living: This company's stock is in an overbought state with an RSI of 80.4, reflecting strong price momentum but also suggesting possible price adjustment risks, prompting investors to monitor market developments closely.
- Amicus Therapeutics Acquisition: Amicus Therapeutics announced its acquisition by BioMarin, with its stock price surging approximately 139% over the past six months to $14.29, while its RSI of 80.4 indicates strong market interest but also warns of potential corrections.
- Mirum Pharmaceuticals Performance: Mirum Pharmaceuticals is also in an overbought condition, and investors should pay attention to its RSI and market performance to assess future investment risks and opportunities.
See More
Mirum Pharmaceuticals Shows Significant Growth in 2025 Performance
- Significant Revenue Growth: Mirum Pharmaceuticals generated $372.4 million in revenue for the nine months ending September 30, 2025, reflecting a 56.8% year-over-year increase, indicating strong market performance despite ongoing unprofitability, laying a foundation for future profitability.
- Quarterly Profit Milestone: In Q3 2025, Mirum reported a rare net profit of $2.9 million, a significant turnaround from a net loss of $14.2 million in the same quarter last year, marking a crucial step toward achieving consistent profitability and potentially attracting more investor interest.
- Future Sales Expectations: The company anticipates net product sales of $520 million for the full 2025 fiscal year, representing at least a 54.4% increase compared to 2024, with projections for 2026 sales reaching between $630 million and $650 million, showcasing robust market demand and growth potential.
- Acquisition Impact: Mirum's recent acquisition of Bluejay Therapeutics for $620 million, while likely to negatively affect short-term profitability due to acquisition costs, is expected to enhance revenue and earnings in the long run by expanding its product lineup and strengthening market competitiveness.
See More
Mirum Pharmaceuticals Reports Third Quarter Profit Amid Slowing Growth
- Third Quarter Profit: Mirum Pharmaceuticals reported a net profit of $2.9 million in Q3 2025, a significant improvement from a net loss of $14.2 million in the same quarter last year, indicating notable progress towards profitability despite remaining unprofitable overall.
- Strong Revenue Growth: For the nine months ending September 30, 2025, Mirum generated $372.4 million in revenue, a 56.8% year-over-year increase, with expectations of $520 million in net product sales for the full fiscal year 2025, reflecting robust market demand.
- Acquisition Impact: The recent acquisition of Bluejay Therapeutics for $620 million may negatively affect short-term profitability due to acquisition costs, but it is expected to enhance revenue and earnings potential in the long run by expanding the product lineup.
- Cautious Future Outlook: While Mirum anticipates net sales of $630 million to $650 million in 2026, representing a 23.1% growth rate, the slowing sales growth raises concerns about the timeline for achieving consistent profitability, necessitating careful risk assessment by investors.
See More
Mirum Pharmaceuticals' Stock Doubles, Poised for Further Gains in 2026
- Positive Cash Flow: Mirum Pharmaceuticals achieved positive cash flow from operations in 2025, marking a significant milestone for a small biotech firm, which is expected to enhance investor confidence and drive stock price appreciation.
- FDA Drug Approvals: In 2025, Mirum received FDA approvals for Ctexli and Livmarli, targeting rare bile acid synthesis disorders and cholestatic pruritus, respectively, which are anticipated to significantly boost revenue and expand market share.
- Acquisition of Bluejay Therapeutics: On January 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding the promising therapy brelovitug for chronic hepatitis delta virus to its pipeline, potentially providing strong momentum for future revenue growth.
- Clinical Trial Catalysts: Mirum is set to announce results from the Phase 2B trial of volixibat in Q2 2026, and if approved, it could fill a treatment gap for primary sclerosing cholangitis in the U.S., further propelling the company's stock price upward.
See More
